NCT07094061 Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
| NCT ID | NCT07094061 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Michigan |
| Condition | Substance Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 294 participants |
| Start Date | 2025-10-03 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 294 participants in total. It began in 2025-10-03 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study seeks to understand individual differences in personality, brain function, and behavior. Study hypothesis: \- A stronger sign-tracking bias will be associated with a bottom-up processing style characterized by less adaptive attentional- and impulse-control as well as hyperactive reward processing, whereas a stronger goal-tracking bias will be associated with a top-down processing style characterized by strong attentional- and impulse-control as well as normative reward processing.
Eligibility Criteria
Inclusion Criteria: * 18-22 years old at baseline * Right-handed * Medically/physically able to give informed consent * English-speaking * Substance use is free to vary, but for participants with a history of substance use, ≥ 1 use of cannabis (including less than a full dose) Exclusion Criteria: * Acute or chronic medical or neurological illness (e.g., diabetes, epilepsy, migraine) * History of psychosis in self or first-degree relative * Current treatment for substance use disorder * Current or past 6-month treatment with centrally acting medications (not including attention deficit hyperactivity disorder (ADHD) medication) * Intelligence quotient (IQ) \< 70 * Lifetime history of head trauma with loss of consciousness \> 5 minutes * Reliance on glasses to be able to read small text at a distance of approximately 30 inches * Colorblindness * MRI contraindication (e.g., pregnancy, metal implants, claustrophobia) per protocol
Contact & Investigator
Lora Cope, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07094061 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 22 Years, studying Substance Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07094061 currently recruiting?
Yes, NCT07094061 is actively recruiting participants. Contact the research team at holdefer@umich.edu for enrollment information.
Where is the NCT07094061 trial being conducted?
This trial is being conducted at Ann Arbor, United States, Ann Arbor, United States.
Who is sponsoring the NCT07094061 clinical trial?
NCT07094061 is sponsored by University of Michigan. The principal investigator is Lora Cope, PhD at University of Michigan. The trial plans to enroll 294 participants.